2、2024年三季报：公司自主研发的口服小分子 GLP-1 受体激动剂 HDM1002，已完成用于超重或肥胖人群的体重管理适应症II期临床研究全部入组，预计于 2024 年 10 月获得顶线结果，预计 2024年 Q4 进行 pre-III期沟通；同时已完成糖尿病适应症 II 期临床研究首例受试者入组。

Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Global Partners LP (NYSE:GLP) Q3 2024 Earnings Call Transcript November 8, 2024 Global Partners LP misses on earnings ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

People are more likely to develop type 2 diabetes if they are: Experts with UW Health say it is important to remember the ...

We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.

The annual meeting of the American College of Gastroenterology was held from Oct. 25 to 30 in Philadelphia and attracted ...